Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...
Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...
We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...
We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company (LLY)'s share ...
If you want to know who really controls Eli Lilly and Company (NYSE:LLY), then you'll have to look at the makeup of its share registry. With 87% stake, institutions possess the maximum shares in ...
Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...
Eli Lilly’s net income doubled compared to Q4 2023, underscoring its robust financial standing. The company’s 2025 revenue guidance ranges between $58.0 billion and $61.0 billion, reflecting continued ...
For years, Eli Lilly has been generating solid growth numbers -- but lately, they've been accelerating rapidly. The company is coming off a solid quarter where its revenue rose by 45% for the last ...
Eli Lilly expands its partnership with AdvanCell to advance targeted alpha therapies using Pb-212 technology for cancer treatment. Lilly inks a global licensing deal with OliX for OLX75016, a ...
We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Eli ...